Donor-derived Cell Free DNA as a Tissue Injury Marker for Early Detection of Acute Rejection and Development of CLAD Following Lung Transplantation in Adults

Overview

About this study

The aim of this study is to evaluate a novel NGS-based assay for early detection of increased amounts of dd-cfDNA and its correlation to acute graft rejection and development of chronic lung allograft dysfunction (CLAD), and to improve the rejection diagnostics of patients after transplantation in order to empower early clinical intervention and thereby prolong the potential survival of the graft.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adults that have had a transplant.

Exclusion Criteria:

Less than 18 years of age.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/15/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla. Mayo Clinic principal investigator Mohamed Elrefaei, M.D., Ph.D.	Open for enrollment	Contact information: Clinical Studies Unit (904) 953-2255

Mayo Clinic Location

Status

Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Mohamed Elrefaei, M.D., Ph.D.

Open for enrollment

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available

Clinical Trials